Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IRIX
stocks logo

IRIX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
FY2025Q1
12.50M
-2.72%
--
--
12.80M
+2.75%
--
--
12.10M
+2.88%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for IRIDEX Corporation (IRIX) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -33.61%.
Revenue Estimates for FY2024
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-33.61%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for IRIDEX Corp (IRIX.O) is -3.48, compared to its 5-year average forward P/E of -8.03. For a more detailed relative valuation and DCF analysis to assess IRIDEX Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.03
Current PE
-3.48
Overvalued PE
-2.99
Undervalued PE
-13.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.77
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.05
Undervalued EV/EBITDA
-12.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.93
Current PS
0.00
Overvalued PS
1.50
Undervalued PS
0.35
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

IRIX News & Events

Events Timeline

(ET)
2025-09-09
16:41:28
Iridex Meets Nasdaq Listing Standards Again
select
2025-06-24 (ET)
2025-06-24
07:03:27
Iridex announces first patient enrolled in investigator-led study of MicroPulse
select
2025-03-19 (ET)
2025-03-19
09:20:49
Iridex appoints Romeo Dizon as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-12Benzinga
LightPath Technologies Shares Rise 7%; Check Out 20 Stocks Making Moves in Premarket Trading

  • LightPath Technologies Performance: LightPath Technologies Inc. shares rose 6.8% in pre-market trading after reporting a quarterly loss of 7 cents per share, which was better than the expected 9-cent loss, alongside revenue of $15.05 million exceeding estimates.

  • Notable Gainers: Salarius Pharmaceuticals surged 170% after announcing pricing for its public offering, while Kandal M Venture and Amaze Holdings also saw significant pre-market gains of 70.4% and 68.4%, respectively.

  • Significant Losers: MSP Recovery Inc. dropped 18.2% in pre-market trading following a previous surge, with other notable declines including Aspire Biopharma and Rain Enhancement Technologies, which fell 16.5% and 14.3%, respectively.

  • Market Overview: The article provides a snapshot of various stocks moving in pre-market trading, highlighting both gainers and losers, along with specific percentage changes in their share prices.

[object Object]
Preview
7.0
09-10SeekingAlpha
Iridex Meets Nasdaq Listing Requirements Again

  • Compliance with Nasdaq: Iridex has received confirmation from Nasdaq that it has regained compliance with continued listing standards after previously being notified of non-compliance regarding stockholders’ equity.

  • Financial Performance: The company met the $2.5 million minimum stockholders’ equity requirement based on its Q2 report, which showed a 14% sequential revenue increase, and is targeting profitability in 2025.

[object Object]
Preview
9.5
08-13NASDAQ.COM
Iridex Reports 7 Percent Q2 Revenue Gain

  • Financial Performance: Iridex reported a 7% year-over-year increase in Q2 2025 GAAP revenue to $13.6 million, with a narrower net loss of $(0.06) per share due to reduced operating expenses and improved sales of certain medical devices, despite declining gross margins.

  • Operational Focus: The company is emphasizing cost control and increasing recurring revenue from consumables, while facing challenges in probe sales; management aims for cash flow breakeven and positive non-GAAP adjusted EBITDA without projecting significant revenue growth.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IRIDEX Corp (IRIX) stock price today?

The current price of IRIX is 0.9294 USD — it has decreased -1.17 % in the last trading day.

arrow icon

What is IRIDEX Corp (IRIX)'s business?

IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.

arrow icon

What is the price predicton of IRIX Stock?

Wall Street analysts forecast IRIX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRIX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IRIDEX Corp (IRIX)'s revenue for the last quarter?

IRIDEX Corp revenue for the last quarter amounts to 12.48M USD, increased 7.80 % YoY.

arrow icon

What is IRIDEX Corp (IRIX)'s earnings per share (EPS) for the last quarter?

IRIDEX Corp. EPS for the last quarter amounts to -0.09 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for IRIDEX Corp (IRIX)'s fundamentals?

The market is revising No Change the revenue expectations for IRIDEX Corporation (IRIX) for FY2024, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -33.61%.
arrow icon

How many employees does IRIDEX Corp (IRIX). have?

IRIDEX Corp (IRIX) has 93 emplpoyees as of December 05 2025.

arrow icon

What is IRIDEX Corp (IRIX) market cap?

Today IRIX has the market capitalization of 15.98M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free